<DOC>
	<DOCNO>NCT02351960</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness symptom control gastroesophageal reflux disease ( GERD ) participant follow treatment dexlansoprazole .</brief_summary>
	<brief_title>Dexlansoprazole Asian Participants With Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . A dual delayed release formulation dexlansoprazole , refer dexlansoprazole Modified Release ( dexlansoprazole MR ) test treat people gastroesophageal reflux disease ( GERD ) . This study look heal esophageal line GERD patient take dexlansoprazole MR . Participants assign two study group base endoscopy screen procedure receive treatment follow : 1. non-erosive reflux disease ( NERD ) group ; dexlansoprazole 30 mg QD 4 week . 2. erosive esophagitis ( EE ) study group ; dexlansoprazole 60 mg QD 8 week , interim clinical evaluation Week 4 clinical evaluation endoscopy week 8 . The study enroll approximately 300 patient ; 200 dexlansoprazole 30 mg QD 100 dexlansoprazole 60 mg group . All participant ask take one capsule morning day throughout study . All participant ask record presence maximum severity daytime nighttime heartburn regurgitation symptom screen , assigned treatment group , throughout duration study use supply paper diary . This multi-centre trial conduct Asia ( Hong Kong , Taiwan , South Korea ) . The overall time participate study 8 week . Participants make 3 visit clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>In opinion investigator , participant capable understand comply protocol requirement The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation procedure Has persistent typical GERD symptom ( heartburn and/or acid regurgitation ) least 6 month frequency GERD symptoms least 4 day within past 7 day prior screen visit Meets one follow diagnosis verify screen endoscopy 1 . Has macroscopically normal esophageal mucosa endoscopy may thereby eligible assignment NERD study group 2 . Has evidence erosive esophageal reflux disease endoscopy , LA Classification Grades BD , thereby may eligible assignment EE study group Is able willing record GERD symptom subject diary complete diary least 7 consecutive day screen period Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study All female participant childbearing potential must negative urine pregnancy test Screening negative urine pregnancy test Day 1 . Participants bilateral tubal ligation , hysterectomy postmenopausal ( absence menses 12 year FollicleStimulating Hormone [ FSH ] level &gt; 40 IU/L absence menses &gt; 2 year ) require use birth control Has receive investigational compound within 30 day prior Screening Known hypersensitivity proton pump inhibitor ( include lansoprazole , omeprazole , rabeprazole , pantoprazole esomeprazole ) , component dexlansoprazole Use H2 blocker PPI dexlansoprazole screen throughout study . Previous use Dexlansoprazole screening Endoscopic Barrett 's esophagus and/or definite dysplastic change esophagus Active gastric duodenal ulcer within 4 week first dose study drug History dilatation esophageal stricture , Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) Coexisting disease affect esophagus , ( eg , esophageal varix , scleroderma , viral , fungal infection esophageal stricture ) , history radiation therapy cryotherapy esophagus , caustic physiochemical trauma sclerotherapy esophagus Chronic use ( &gt; 12 doses/month ) non ; steroidal antiinflammatory drug ( NSAIDs ) include COX 2 NSAIDs within 30 day prior screen period throughout study , however , low dose aspirin 325 mg per day allow In judgment investigator , participant clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes Screening Has history clinical manifestation significant organ failure would preclude successful completion study Participants use drug significant anticholinergic effect tricyclic stay stable dose 4 week prior dose throughout study Participants know biliary disease Participants need continuous anticoagulant therapy Participants cancer ( except basal cell squamous cell carcinoma skin ) within 3 year prior Screening Any condition may require inpatient surgery course study Has abnormal laboratory value suggest clinically significant underlying disease condition may prevent subject enter study ; subject follow lab abnormality : Creatinine &gt; 1.5 mg/dL , Alanine Aminotransferase ( ALT ) and/or Aspartate Aminotransferase ( AST ) &gt; 2.0X upper limit normal , Total Bilirubin &gt; 2.0 mg/dL AST/ALT elevate normal value Known acquire immunodeficiency syndrome ( AIDS ) Current historical evidence ZollingerEllison syndrome hypersecretory condition History gastric , duodenal esophageal surgery except simple oversew ulcer Acute upper gastrointestinal ( UGI ) hemorrhage within 4 week endoscopy Has receive blood product within 3 month prior first dose study drug History alcohol abuse [ &gt; 21 unit ( 1 unit = 12 oz beer , 1.5 oz hard liquor , 5 oz wine ) per week ] illegal drug use drug addiction 12 month prior Screening Participants , opinion investigator , unable comply requirement study unsuitable reason require take exclude medication If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period If male , participant intend donate sperm course study 30 day thereafter</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug therapy</keyword>
	<keyword>GERD</keyword>
	<keyword>Dexlansoprazole</keyword>
</DOC>